Life-science venture capital firm Westlake Village BioPartners is launching a $450 million fund to incubate and grow early-stage biotechnology companies in the Los Angeles region.
Marking the firm’s third fund, the investment aims to match next-generation biotech companies with talent, furthering the development of life-saving technologies.
The fund will be managed by Westlake Village BioPartners managing directors Beth Seidenberg, Mira Chaurushiya and David Allison. Both Chaurushiya and Allison were made managing directors at Westlake in conjunction with the start of the new fund.
In 2020, the firm launched its first two funds totaling $500 million to build and invest in “promising” life-science companies with transformative human therapeutic technologies.
With nearly $1 billion allotted for funding, Westlake Village BioPartners has invested in the development of more than 20 companies, such as biotech companies Arsenal Biosciences, Kate Therapeutics, Recludix Pharma and Acelyrin.
Located at 3075 Townsgate Rd. in Westlake Village, California, Westlake Village BioPartners launched in 2018 by Seidenberg and Sean Harper, two former employees of biotech giant Amgen.
